Real-time Artificial Intelligence-based Speech Enhancement Methods for Hearing Aid Improvement

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Individuals with Auditory Neuropathy Spectrum Disorders (ANSD) represent 1-10% of adults with hearing loss. These individuals have little or no benefit from current hearing aids because ANSD is a continuum of hearing impairments due to synaptic or neural dysfunction in the peripheral and central parts of the auditory pathways, which impairs temporal information processing without necessarily affecting auditory sensitivity. There is a need to find ad-hoc denoising methods, based on the expert knowledge of audiologists, to improve the noise comprehension performance of these patients. Implemented denoising methods, based on artificial intelligence, will also greatly benefit more standard hearing loss cases.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: t
View:

⁃ For all participants:

• Age greater than or equal to 18 years,

• French mother tongue,

• Have an average tonal hearing loss (calculated according to the BIAP method) \< 30 dB HL, on headphones, for each ear,

• Be professionally active, not be pre-retired and not be unemployed

• Be affiliated with a social security plan,

⁃ For participants with TSNA:

⁃ \- Have degraded comprehension in noise (threshold of Intelligibility in Noise \> 3 dB compared to the norm).

⁃ For controls:

⁃ \- Have normal comprehension in noise (Intelligibility in Noise threshold ≤ 3 dB from the norm).

Locations
Other Locations
France
CEntre de Recherche et d'Innovation en Audiologie Humaine
RECRUITING
Paris
Contact Information
Primary
Marta Campi, PhD
marta.campi@pasteur.fr
++33 (0) 1 76 53 51 12
Backup
Paul Avan, MD
paul.avan@uca.fr
+33 (0)1 76 53 50 94
Time Frame
Start Date: 2024-03-06
Estimated Completion Date: 2026-09-15
Participants
Target number of participants: 40
Treatments
Other: Professionally active adults with a moderate hearing loss
Related Therapeutic Areas
Sponsors
Leads: Institut Pasteur

This content was sourced from clinicaltrials.gov